#Liechtenstein #RefluxStop™ #AGM 2025 #Implantica AG #Ruggell

Implantica AG Invites Depository Receipt Holders to Annual General Meeting

Implantica AG, a prominent player in the medtech sector, has officially called upon its depository receipt holders to participate in the upcoming Annual General Meeting (AGM). The meeting is slated for Thursday, May 15, 2025, commencing at 2:00 PM at the Hotel Kommod, located in Ruggell, Liechtenstein.

Participation Requirements

To attend the AGM, potential attendees must be listed as depository receipt holders in the Swedish Depository Receipt (SDR) register. This registration needs to be completed by April 30, 2025, and participants are encouraged to notify Implantica of their intent to attend by May 7, 2025.

The notification can be sent via email to [email protected] or mailed to Implantica AG, Annual General Meeting, Aeulestrasse 45, 9490 Vaduz, Liechtenstein. When notifying the company, participants should include their full name, personal identity or company registration number, address, phone number, and the number of representatives (which cannot exceed two).

For those unable to attend in person, there is an option to cast votes via postal voting, adhering to the instructions provided on the designated voting form. This form must also be sent to Pareto Securities AB, the custodian, no later than May 7, 2025. If attendees wish to have a proxy represent them at the meeting, a signed power of attorney dated within the last year must be provided, along with documentation to verify the proxy's authority to act on behalf of the legal entity.

Proposed Agenda Items

The AGM's agenda includes key resolutions, such as:
1. Opening of the meeting and appointment of the Chair.
2. Approval of the voting list and agenda.
3. CEO and CFO addresses.
4. Presentation and adoption of the annual financial statements and auditor reports.
5. Determination of the net result as per the balance sheet.
6. Discharge of the Board of Directors and management for the fiscal year 2024.
7. Approval of remuneration for the Board and Executive Management.
8. Elections for the Board of Directors, including Chair and Vice-Chair.
9. Election of the Nomination and Remuneration Committee members.
10. Appointment of the independent proxy and auditors.
11. Amendments to specific articles of the company’s Articles of Association.

Financial Year Highlights

For the year ending 2024, Implantica reports a carry forward of the net loss, recommending no dividend payout based on the adopted balance sheet. Furthermore, each member of the Board and Executive Management is seeking discharge for their actions throughout the financial year.

Future Goals and Innovations

Implantica is focused on innovating within the medtech realm, primarily with its flagship product, the RefluxStop™, designed to revolutionize treatment for gastroesophageal reflux. The AGM provides an opportunity for shareholders to understand the current trajectory of the company's growth and future missions, particularly in advancing health monitoring technology within the human body.

Documentation and Queries

Shareholders can access comprehensive documents related to the AGM, including the complete proposals and annual reports, at Implantica’s office from three weeks prior to the meeting or via the company’s official website. Additionally, any questions beforehand may be directed to Implantica through the provided contact emails.

The annual meeting represents a critical moment for shareholders of Implantica AG, presenting them with the platform to engage with management’s strategies for the future and their overall vision for the company.